We further assessed whether targeting CD73 could enhance the therapeutic activity of anti-PD-1 monoclonal antibodies (mAbs) using an AKT/NICD-induced spontaneous iCCA model. This evidence concerns the gene AKT1 and infantile convulsions and choreoathetosis.